Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (EYPT), Omada Health, Inc. (OMDA) and BridgeBio Oncology Therapeutics (BBOT)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on EyePoint Pharmaceuticals (EYPT – Research Report), Omada Health, Inc. (OMDA – Research Report) and BridgeBio Oncology Therapeutics (BBOT – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
EyePoint Pharmaceuticals (EYPT)
JonesTrading analyst Debanjana Chatterjee reiterated a Buy rating on EyePoint Pharmaceuticals today and set a price target of $43.00. The company’s shares closed last Thursday at $15.76.
According to TipRanks.com, Chatterjee is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for EyePoint Pharmaceuticals with a $39.71 average price target, which is a 120.9% upside from current levels. In a report issued on February 19, Mizuho Securities also maintained a Buy rating on the stock with a $36.00 price target.
See the top stocks recommended by analysts >>
Omada Health, Inc. (OMDA)
Morgan Stanley analyst Craig Hettenbach reiterated a Buy rating on Omada Health, Inc. today and set a price target of $30.00. The company’s shares closed last Thursday at $13.60.
According to TipRanks.com, Hettenbach is ranked #2946 out of 12128 analysts.
Currently, the analyst consensus on Omada Health, Inc. is a Strong Buy with an average price target of $23.57, a 74.6% upside from current levels. In a report issued on February 23, Evercore ISI also maintained a Buy rating on the stock with a $25.00 price target.
BridgeBio Oncology Therapeutics (BBOT)
In a report released today, Biren Amin from Piper Sandler maintained a Buy rating on BridgeBio Oncology Therapeutics, with a price target of $21.00. The company’s shares closed last Thursday at $9.89.
According to TipRanks.com, Amin is a 4-star analyst with an average return of
Currently, the analyst consensus on BridgeBio Oncology Therapeutics is a Strong Buy with an average price target of $23.33, representing a 129.4% upside. In a report released today, Stifel Nicolaus also maintained a Buy rating on the stock with a $23.00 price target.
